Form 4: Pliant Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Smital Shah acquired stock options in Pliant Therapeutics, according to a recent SEC filing.
Summary
- Smital Shah, a director of Pliant Therapeutics, acquired options to purchase 26,764 shares of common stock on June 13, 2024.
- The exercise price of these options is $13.06 per share.
- The options vest quarterly, with 25% vesting on the first day of each calendar quarter for three quarters following the grant date.
- The remaining 25% vests on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, contingent on continued service as a director.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock option grants, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder confidence as it shows a director increasing their stake in the company.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of the stock option grant and initial transaction. |
| 06/13/2034 | Expiration date of the stock options. |
| 06/17/2024 | Date of the SEC filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.